ALZFORUM LIVE WEBINAR: Computational Modeling—Will it Rescue AD Clinical Trials?

The Alzheimer's field has had its share of clinical trial flops. Now there's a push to learn from past failures. Computational scientists in pharmaceutical companies are guiding clinical trial design by first putting drug candidates through their paces in simulations. Those are proprietary, but C-Path’s Coalition Against Major Diseases has built some open-access simulation tools

No comments: